Evaxion Biotech A/S (EVAX) News Today → Obama’s Forever Term [exposed] (From Porter & Company) (Ad) Free EVAX Stock Alerts $3.83 -0.21 (-5.20%) (As of 05/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 28 at 1:38 PM | finanznachrichten.deEvaxion Biotech: Evaxion Announces Business Update and First Quarter 2024 Financial ResultsMay 28 at 8:21 AM | globenewswire.comEvaxion Announces Business Update and First Quarter 2024 Financial ResultsMay 24, 2024 | finance.yahoo.comEvaxion Biotech Plans to Unveil 'Positive' Data From Phase 2 Study of Advanced Melanoma Combination TreatmentMay 23, 2024 | globenewswire.comEvaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024May 11, 2024 | finanznachrichten.deEvaxion Biotech: Evaxion Receives Nasdaq NotificationMay 10, 2024 | globenewswire.comEvaxion Receives Nasdaq NotificationApril 17, 2024 | msn.comEvaxion Biotech A (EVAX) Price Target Decreased by 13.62% to 11.99April 17, 2024 | finanznachrichten.deEvaxion Biotech: Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01April 17, 2024 | finance.yahoo.comEvaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01April 17, 2024 | globenewswire.comEvaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01April 3, 2024 | finance.yahoo.comQ4 2023 Evaxion Biotech A/S Earnings Call (Danish)April 3, 2024 | finance.yahoo.comEvaxion Biotech A/S (NASDAQ:EVAX) Q4 2023 Earnings Call TranscriptApril 2, 2024 | marketwatch.comADRs End Lower; Meta Data Slides 22%April 2, 2024 | globenewswire.comEvaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus InfectionMarch 28, 2024 | finanznachrichten.deEvaxion Biotech: Evaxion Announces Business Update and Full Year 2023 Financial ResultsMarch 27, 2024 | investorplace.comEVAX Stock Earnings: Evaxion Biotech Meets EPS for Q4 2023March 27, 2024 | globenewswire.comEvaxion Announces Business Update and Full Year 2023 Financial ResultsMarch 22, 2024 | finance.yahoo.comWhen Will Evaxion Biotech A/S (NASDAQ:EVAX) Turn A Profit?March 20, 2024 | markets.businessinsider.comBuy Rating Affirmed for Evaxion Biotech Amid AI-Driven Vaccine Development MilestonesMarch 19, 2024 | finanznachrichten.deEvaxion Biotech: Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology PlatformMarch 19, 2024 | globenewswire.comEvaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ PlatformMarch 13, 2024 | msn.comNeuroBo Phase 2a study for MASH drug to proceed as plannedFebruary 29, 2024 | globenewswire.comEvaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology InnovationsFebruary 24, 2024 | msn.comEvaxion Biotech A (EVAX) Price Target Increased by 414.29% to 18.36February 20, 2024 | finanznachrichten.deEvaxion Biotech: Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSDFebruary 20, 2024 | finance.yahoo.comEvaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSDFebruary 20, 2024 | globenewswire.comEvaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSDFebruary 12, 2024 | markets.businessinsider.comBuy Rating for Evaxion Biotech: AI Revolutionizing Immunotherapy and Vaccine DevelopmentFebruary 7, 2024 | investing.comEvaxion Biotech AS (EVAX)February 7, 2024 | finance.yahoo.comEvaxion Regains Compliance with Nasdaq Minimum Bid Price RequirementFebruary 6, 2024 | finanznachrichten.deEvaxion Biotech: Evaxion Announces Closing of $15 Million Public OfferingFebruary 6, 2024 | finance.yahoo.comEvaxion Announces Closing of $15 Million Public OfferingFebruary 1, 2024 | msn.comEvaxion Biotech to raise ~$15M through public offering of shares and warrantsFebruary 1, 2024 | marketbeat.comTrading was temporarily halted for "EVAX" at 09:02 AM with a stated reason of "LULD pause."February 1, 2024 | finance.yahoo.comEvaxion Biotech Announces Pricing of $15 Million Public OfferingFebruary 1, 2024 | marketbeat.comTrading was temporarily halted for "EVAX" at 09:02 AM with a stated reason of "LULD pause."January 29, 2024 | marketbeat.comTrading was temporarily halted for "EVAX" at 09:01 AM with a stated reason of "LULD pause."January 25, 2024 | msn.comEvaxion Biotech to develop new vaccines for cancerJanuary 24, 2024 | morningstar.comADRs Close Higher, Evaxion Biotech A/S Climbs 113.4%January 24, 2024 | msn.comEvaxion stock rallies 120% on AI-based cancer vaccine programJanuary 24, 2024 | marketbeat.comTrading was temporarily halted for "EVAX" at 10:01 AM with a stated reason of "LULD pause."January 24, 2024 | marketbeat.comTrading was temporarily halted for "EVAX" at 10:01 AM with a stated reason of "LULD pause."January 24, 2024 | marketbeat.comTrading was temporarily halted for "EVAX" at 09:01 AM with a stated reason of "LULD pause."January 24, 2024 | finanznachrichten.deEvaxion Biotech: Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered TargetsJanuary 24, 2024 | marketwatch.comEvaxion ADSs Rise 17% After ADS Ratio ChangeJanuary 24, 2024 | finance.yahoo.comEvaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered TargetsJanuary 23, 2024 | marketbeat.comTrading was temporarily halted for "EVAX" at 09:01 AM with a stated reason of "LULD pause."January 22, 2024 | finanznachrichten.deEvaxion Biotech: Evaxion Announces Completion of ADS Ratio ChangeJanuary 22, 2024 | morningstar.comADRs End Lower; Evaxion Biotech A/S Drops 45%January 22, 2024 | finance.yahoo.comEvaxion Announces Completion of ADS Ratio Change Get Evaxion Biotech A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for EVAX and its competitors with MarketBeat's FREE daily newsletter. Email Address You won't believe what Citigroup just did to it's depositors (Ad)The FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st This guide shows you what to do next. In a cashless society, Biden forces you to use the government's new "digital dollar"... CLICK HERE TO GET YOUR GUIDE NOW EVAX Media Mentions By Week EVAX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EVAX News Sentiment▼0.820.79▲Average Medical News Sentiment EVAX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EVAX Articles This Week▼71▲EVAX Articles Average Week Get Evaxion Biotech A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for EVAX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CASI Pharmaceuticals News Today Champions Oncology News Today AlloVir News Today Gritstone bio News Today BioAtla News Today Elutia News Today Atara Biotherapeutics News Today Instil Bio News Today Passage Bio News Today AVROBIO News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EVAX) was last updated on 5/29/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaA once-in-a-century investment opportunityStansberry ResearchWrite this ticker symbol down…StocksToTradeYou won't believe what Citigroup just did to it's depositorsAmerican AlternativeMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceHe Is Giving Away BitcoinCrypto Swap ProfitsBill Clinton Backing Biden Replacement???The Freeport Society Adding Choose a watchlist: Watchlist My Default Watchlist Adding Evaxion Biotech A/S You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
